NCT00649441

Fasting Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg

Single-Dose Fasting In Vivo Bioequivalence Study of Quinapril HCl and Hydrochlorothiazide Tablets (20 mg/25 mg; Mylan) to Accuretic™ Tablets (20 mg/25 mg; Parke-Davis) in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Mylan Pharmaceuticals Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The objective of this study was to investigate the bioequivalence of Mylan's quinapril HCl and hydrochlorothiazide 20 mg/25 mg tablets to Parke-Davis' Accuretic™ 20 mg/25 mg tablets following a single, oral 20 mg/25 mg (1 x 20 mg/25 mg) dose administered under fasting conditions.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg	20/25mg, single dose fasting
DRUG	Accuretic™ Tablets 20 mg/25 mg	20/25mg, single dose fasting

Timeline

• Start date: 2003-08-01
• Primary completion: 2003-09-01
• Completion: 2003-09-01
• First posted: 2008-04-01
• Last updated: 2024-04-24

Locations

1 site across 1 country: United States